Innovent Biologics Inc.
IVBXF | OTC
$10.53
+$0.63 (+6.36%)
Nov 2, 2026, 10:30 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 13.04B | 9.42B | 6.21B | 4.56B | 4.27B | 3.84B |
Cost of Revenue | 3.04B | 1.51B | 1.81B | 930.99M | 573.04M | 387.76M |
Gross Profit | 10B | 7.91B | 4.4B | 3.63B | 3.7B | 3.46B |
Operating Income | 733.62M | -755.87M | -1.68B | -3.12B | -2.7B | -557.19M |
Interest Income | 427.33M | 423.45M | 452.84M | 189.54M | 151.76M | 116.1M |
Pretax Income | 838.92M | -78.62M | -1.14B | -2.17B | -2.64B | -858.71M |
Net Income | 813.57M | -94.63M | -1.03B | -2.18B | -2.73B | -998.42M |
Selling & General & Admin | 6.64B | 5.08B | 3.85B | 3.43B | 3.61B | 1.78B |
Research & Development | 2.62B | 2.68B | 2.23B | 2.87B | 2.48B | 1.85B |
Other Expenses | n/a | -112.45M | n/a | -90.2M | -341.6M | -130.69M |
Operating Expenses | 9.26B | 7.65B | 6.08B | 6.21B | 5.75B | 3.5B |
Interest Expense | 77.54M | 67.65M | 98.62M | 101.7M | 62.46M | 68.35M |
Selling & Marketing Expenses | 5.71B | 4.35B | 3.1B | 2.59B | 2.62B | 1.34B |
Cost & Expenses | 12.31B | 9.16B | 7.89B | 7.68B | 6.97B | 4.4B |
Income Tax Expense | 25.36M | 16.01M | -116.5M | 8.8M | 87.04M | 139.71M |
Shares Outstanding (Basic) | 1.73B | 1.63B | 1.56B | 1.49B | 1.45B | 1.35B |
Shares Outstanding (Diluted) | 1.74B | 1.63B | 1.56B | 1.49B | 1.46B | 1.36B |
EPS (Basic) | 0.48 | -0.06 | -0.66 | -1.46 | -1.88 | -0.74 |
EPS (Diluted) | 0.47 | -0.06 | -0.66 | -1.46 | -1.88 | -0.74 |
EBITDA | 1.31B | -480.28M | -660.68M | -1.75B | -2.37B | -704.74M |
EBIT | 733.62M | -755.87M | -1.05B | -2.07B | -2.58B | -790.36M |
Depreciation & Amortization | 576.53M | 275.6M | 385.1M | 319.42M | 204.75M | 85.63M |
Add to Watchlist
Select watchlists to add or remove IVBXF